Collectively, our data indicate that MNK inhibition enhances the inhibitory effects of chemotherapeutic drugs in breast cancer cells, most likely by enhancing eIF4E phosphorylation and β-catenin activation. The gene discussed is EIF4E; the disease is breast carcinoma.